XML 52 R42.htm IDEA: XBRL DOCUMENT
v3.22.1

License and Collaboration Agreements - Additional Information (Details) |  | 1 Months Ended | 3 Months Ended | 12 Months Ended | 55 Months Ended | 56 Months Ended |
--- | --- | --- | --- | --- | --- | --- | ---
Jul. 13, 2020 USD ($) Program $ / shares shares | Jan. 31, 2022 USD ($) | Nov. 30, 2021 USD ($) Program | Jan. 31, 2021 USD ($) $ / shares shares | Nov. 30, 2019 USD ($) | Sep. 30, 2017 USD ($) | Aug. 31, 2017 USD ($) | Mar. 31, 2022 USD ($) | Mar. 31, 2021 USD ($) | Dec. 31, 2021 USD ($) | Dec. 31, 2020 USD ($) $ / shares shares | Dec. 31, 2017 USD ($) | Mar. 31, 2022 USD ($) | Mar. 31, 2022 USD ($) | Dec. 30, 2021 USD ($)
License And Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Total collaboration and license revenues |  |  |  |  |  |  |  | $ 18,005,000 | $ 9,461,000 |  |  |  |  |  |
Option continuation payment due upon second anniversary of agreement |  |  |  |  |  |  |  |  |  | $ 100,000,000 |  |  |  |  |
Deferred revenue recognized |  |  |  |  |  |  |  | 18,005,000 | 9,461,000 |  |  |  |  |  |
Remaining capitalized fees at closing |  |  |  |  |  |  |  |  |  | 3,800,000 |  |  |  |  |
Fees allocated among performance obligations |  |  |  |  |  |  |  |  |  | 8,300,000 |  |  |  |  |
Development milestone expense |  |  |  |  |  |  |  |  | 0 |  |  |  |  |  |
Development expense |  |  |  |  |  |  |  | 61,211,000 | 66,387,000 |  |  |  |  |  |
Contract with customer liability, noncurrent |  |  |  |  |  |  |  | 456,905,000 |  | 462,217,000 |  |  | $ 456,905,000 | $ 456,905,000 |
Gilead |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
License And Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Fee incurred to third party upon receipt of option exercise payments |  |  |  |  |  |  |  |  |  | 4,500,000 |  |  |  |  |
WuXi Biologics License Agreement |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
License And Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Clinical and regulatory milestones achieved |  |  |  |  |  |  |  | $ 16,500,000 |  |  |  |  |  |  |
Range of tiered royalty payments on net sales |  |  |  |  |  |  |  | high single-digits to low teens |  |  |  |  |  |  |
Development milestone expense |  |  |  |  |  |  |  | $ 1,500,000 |  |  |  |  |  |  |
WuXi Biologics License Agreement | Research and Development |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
License And Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Upfront cash payment |  |  |  |  |  |  |  | 500,000 |  |  |  |  |  |  |
Sub-license fees incurred |  |  |  |  |  |  |  | 0 | 0 |  |  |  |  | 11,300,000 |
Upfront and milestone payments |  |  |  |  |  |  |  |  |  |  |  |  |  | 41,000,000.0 |
Development milestone payments |  |  |  |  |  |  |  | 1,500,000 |  |  |  |  |  |  |
Milestone payments |  |  |  |  |  |  |  | 0 | 10,000,000 |  |  |  |  |  |
WuXi Biologics License Agreement | Maximum |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
License And Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Clinical, regulatory and commercialization milestone payments |  |  |  |  |  |  | $ 375,000,000.0 |  |  |  |  |  |  |  |
Abmuno License Agreement |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
License And Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Upfront and milestone payments |  |  |  |  |  |  |  | 14,600,000 |  |  |  |  |  |  |
Clinical, regulatory and commercialization remaining milestone payments |  |  |  |  |  |  |  | 93,000,000.0 |  |  |  |  |  |  |
Development milestone expense |  |  |  |  |  |  |  | 5,000,000.0 | 5,000,000.0 |  |  |  |  |  |
Genentech |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
License And Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Development expense |  |  |  |  |  |  |  | 300,000 | 300,000 |  |  |  |  |  |
Gilead Collaboration Agreement |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
License And Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Option payment upon completion of certain IND-enabling activities | $ 60,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Option payment upon achievement of certain development milestones | 150,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred revenue |  |  |  |  |  |  |  | 542,900,000 |  | 559,200,000 |  |  | 542,900,000 | 542,900,000 |
Increase (Decrease) in Operating expenses |  |  |  |  |  |  |  | (30,400,000) | (4,900,000) |  |  |  |  |  |
Gilead Collaboration Agreement | Gilead |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
License And Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Upfront cash payment | $ 175,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration term for current and future clinical programs | 10 years |  |  |  |  |  |  |  |  |  |  |  |  |  |
Contingent milestone payments receivable | $ 300,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Additional collaboration term for programs entering clinical development prior to end of collaboration term | 3 years |  |  |  |  |  |  |  |  |  |  |  |  |  |
Option continuation payment receivable upon eighth anniversary of agreement | $ 100,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Option continuation payment receivable upon fourth anniversary of agreement | 100,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Option continuation payment receivable upon sixth anniversary of agreement | 100,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Option fee per program for all other programs entering clinical development to exercise option | $ 150,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of research programs | Program | 2 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Option payment upon achievement of certain development milestones | $ 250,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Total collaboration and license revenues |  |  |  |  |  |  |  | 5,000,000.0 |  |  |  |  |  |  |
Deferred revenue |  |  |  |  |  |  |  | 213,800,000 |  |  |  |  | 213,800,000 | 213,800,000 |
Deferred revenue related to domvanalimab option |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 36,700,000
Deferred revenue recognized |  |  |  |  |  |  |  |  |  | 328,800,000 |  |  |  |  |
Deferred revenue related to etrumadenant option |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 127,000,000.0
Option payment upon achievement of certain development milestones | $ 275,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Current and future programs exclusive access period | 10 years |  |  |  |  |  |  |  |  |  |  |  |  |  |
Performance obligation period | 4 years |  |  |  |  |  |  |  |  |  |  |  |  |  |
Contractual obligation remaining amount not obligated to pay | $ 300,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred revenue related to research and development pipeline |  |  |  |  |  |  |  | 111,900,000 |  |  |  |  | 111,900,000 | 111,900,000 | $ 91,700,000
Consultant and legal fees | 7,300,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Capitalized costs |  |  |  |  |  |  |  | 100,000 | 100,000 |  |  |  |  |  |
Cost sharing receivable |  |  |  |  |  |  |  | 4,800,000 |  |  |  |  | 4,800,000 | 4,800,000 |
Gilead Collaboration Agreement | Gilead | Prepaid Expenses and Other Current Assets |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
License And Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Capitalized costs to obtain the contract, current |  |  |  |  |  |  |  | 800,000 |  |  |  |  | 800,000 | 800,000 |
Gilead Collaboration Agreement | Gilead | Other Noncurrent Assets |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
License And Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Receivable from collaboration partners- noncurrent |  |  |  |  |  |  |  | 1,100,000 |  |  |  |  | 1,100,000 | 1,100,000 |
Capitalized costs to obtain the contract, noncurrent |  |  |  |  |  |  |  | 4,000,000.0 |  |  |  |  | 4,000,000.0 | 4,000,000.0 |
Gilead Collaboration Agreement | Gilead | Maximum |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
License And Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Contingent milestone payments receivable | 300,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Potential regulatory approval milestones payment receivable related to domvanalimab | 500,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Gilead Collaboration Agreement | Taiho Pharmaceutical Co., Ltd |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
License And Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Option period |  |  |  |  |  | 5 years |  |  |  |  |  |  |  |  |
Option ending period |  |  |  |  |  | 2022-09 |  |  |  |  |  |  |  |  |
Non refundable and non creditable cash payments |  |  |  |  |  |  |  |  |  |  |  | $ 35,000,000.0 |  |  |
Payment for first option exercise |  |  | $ 15,000,000.0 |  |  |  |  |  |  |  |  |  |  |  |
Purchase Agreement |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
License And Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Direct offering cost | 1,900,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Purchase Agreement | Gilead |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
License And Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Issuance of common stock | $ 200,000,000 |  |  |  |  |  |  |  | 220,296,000 |  |  |  |  |  |
Issuance of common stock, shares | shares | 5,963,029 |  |  |  |  |  |  |  |  |  | 5,963,029 |  |  |  |
Shares issued, price per share | $ / shares | $ 33.54 |  |  |  |  |  |  |  |  |  | $ 33.54 |  |  |  |
Percentage of option to purchase maximum shares of common stock | 35.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |
Period over common stock to be purchased | 5 years |  |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of premium purchase price of common stock | 20.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |
Trailing days average closing price | 5 days |  |  |  |  |  |  |  |  |  |  |  |  |  |
Share Price | $ / shares | $ 33.54 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Funds received for purchase of common stock |  |  |  |  |  |  |  |  |  |  | $ 200,000,000 |  |  |  |
Purchase price of common stock allocation to performance obligation |  |  |  |  |  |  |  |  |  |  | $ 90,600,000 |  |  |  |
Purchase Agreement | Gilead | May 2020 Public Offering |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
License And Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Shares issued, price per share | $ / shares |  |  |  |  |  |  |  |  |  |  | $ 27.50 |  |  |  |
Additional equity investment net of offering costs |  |  |  |  |  |  |  |  |  |  | $ 56,700,000 |  |  |  |
Additional equity investment shares issued | shares |  |  |  |  |  |  |  |  |  |  | 2,200,000 |  |  |  |
Amended Gilead Collaboration Agreement |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
License And Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Upfront cash payment |  |  |  |  |  |  |  |  |  | 725,000,000 |  |  |  |  |
Issuance of common stock |  |  |  | $ 220,300,000 |  |  |  |  |  |  |  |  |  |  |
Issuance of common stock, shares | shares |  |  |  | 5,650,000 |  |  |  |  |  |  |  |  |  |  |
Shares issued, price per share | $ / shares |  |  |  | $ 39.00 |  |  |  |  |  |  |  |  |  |  |
Option payments received |  | $ 725,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |
Number of exercise option to programs | Program |  |  | 3 |  |  |  |  |  |  |  |  |  |  |  |
Removal of option continuation payment under agreement |  |  | $ 100,000,000 |  |  |  |  |  |  |  |  |  |  |  |
Deferred revenue |  |  |  |  |  |  |  |  |  | 165,100,000 |  |  |  |  |
Initial transaction price |  |  |  |  |  |  |  |  |  | 890,100,000 |  |  |  |  |
Maximum ownership percentage of outstanding common stock remain unchanged |  |  |  | 35.00% |  |  |  |  |  |  |  |  |  |  |
Quemliclustat Option, and R&D Activities Agreement |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
License And Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Option payment upon achievement of certain development milestones |  |  |  |  |  |  |  | 200,000,000 |  |  |  |  |  |  |
Total collaboration and license revenues |  |  |  |  |  |  |  | 1,800,000 |  |  |  |  |  |  |
Deferred revenue |  |  |  |  |  |  |  | 173,800,000 |  |  |  |  | 173,800,000 | 173,800,000 |
R&D activities for Domvanalimab |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
License And Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Total collaboration and license revenues |  |  |  |  |  |  |  | 900,000 |  |  |  |  |  |  |
Deferred revenue |  |  |  |  |  |  |  | 33,600,000 |  |  |  |  | 33,600,000 | 33,600,000 |
R&D and Commercialization Activities for Zimberelimab Monotherapy |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
License And Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred revenue related to development and commercialization services |  |  |  |  |  |  |  | 9,700,000 |  |  |  |  | 9,700,000 | 9,700,000 |
Total collaboration and license revenues |  |  |  |  |  |  |  | 300,000 |  |  |  |  |  |  |
Deferred revenue |  |  |  |  |  |  |  | 9,800,000 |  |  |  |  | 9,800,000 | 9,800,000 |
Access Rights related to Research and Development Pipeline |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
License And Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Total collaboration and license revenues |  |  |  |  |  |  |  | $ 8,300,000 | 7,700,000 |  |  |  |  |  |
Taiho Agreement | Taiho Pharmaceutical Co., Ltd |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
License And Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Payment for option exercise |  |  |  |  | $ 8,000,000.0 |  |  |  |  |  |  |  | 26,000,000.0 |  |
Range of royalties receivable on net sales |  |  |  |  |  |  |  | high single-digits to mid-teens |  |  |  |  |  |  |
Royalties payable description |  |  |  |  |  |  |  | Royalties will be payable on a licensed product-by-licensed product and country-by-country basis during the period of time commencing on the first commercial sale of a licensed product in a country and ending upon the later of: (a) ten (10) years from the date of first commercial sale of such licensed product in such country; and (b) expiration of the last-to-expire valid claim of the Company’s patents covering the manufacture, use or sale or exploitation of such licensed product in such country (the Royalty Term). |  |  |  |  |  |  |
Non-refundable, non-creditable upfront cash payments |  |  |  |  |  |  |  | $ 35,000,000.0 |  |  |  |  |  |  |
Estimated performance period |  |  |  |  |  |  |  | 5 years |  |  |  |  |  |  |
Clinical and regulatory milestones achieved |  |  |  |  |  |  |  | $ 0 |  |  |  |  |  |  |
Sales milestone or royalty revenue recognized |  |  |  |  |  |  |  | 0 |  |  |  |  |  |  |
Deferred revenue, current |  |  |  |  |  |  |  | 3,300,000 |  | $ 5,000,000.0 |  |  | 3,300,000 | 3,300,000 |
Taiho Agreement | Taiho Pharmaceutical Co., Ltd | Minimum |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
License And Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Payment for option exercise |  |  |  |  |  | $ 3,000,000.0 |  |  |  |  |  |  |  |  |
Taiho Agreement | Taiho Pharmaceutical Co., Ltd | Maximum |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
License And Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Contingent milestone payments receivable |  |  |  |  |  | 145,000,000.0 |  |  |  |  |  |  |  |  |
Payment for option exercise |  |  |  |  |  | 15,000,000.0 |  |  |  |  |  |  |  |  |
Additional clinical and regulatory milestone payments receivable |  |  |  |  |  | $ 130,000,000.0 |  |  |  |  |  |  |  |  |
AstraZeneca Agreement |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
License And Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Development cost recorded within research and development expenses |  |  |  |  |  |  |  | 1,200,000 | $ 0 |  |  |  |  |  |
AstraZeneca Agreement | Other Long-term Liabilities |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
License And Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Contract with customer liability, noncurrent |  |  |  |  |  |  |  | 2,300,000 |  |  |  |  | $ 2,300,000 | $ 2,300,000 |
Genentech Collaboration Agreement | Genentech |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
License And Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Development cost recorded within research and development expenses |  |  |  |  |  |  |  | $ 1,800,000 |  |  |  |  |  |  |

X
- Definition Additional clinical and milestone payments received under license agreement. + References No definition available. + Details
Name: | rcus_AdditionalClinicalAndMilestonePaymentsReceivedUnderLicenseAgreement
Namespace Prefix: | rcus_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Additional collaboration term for programs entering clinical development prior to end of collaboration term. + References No definition available. + Details
Name: | rcus_AdditionalCollaborationTermForProgramsEnteringClinicalDevelopmentPriorToEndOfCollaborationTerm
Namespace Prefix: | rcus_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Additional equity investment net of offering costs. + References No definition available. + Details
Name: | rcus_AdditionalEquityInvestmentNetOfOfferingCosts
Namespace Prefix: | rcus_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Additional equity investment shares issued. + References No definition available. + Details
Name: | rcus_AdditionalEquityInvestmentSharesIssued
Namespace Prefix: | rcus_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Clinical and regulatory milestones achieved under license agreement. + References No definition available. + Details
Name: | rcus_ClinicalAndRegulatoryMilestonesAchievedUnderLicenseAgreement
Namespace Prefix: | rcus_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Clinical regulatory and commercialization milestone payments. + References No definition available. + Details
Name: | rcus_ClinicalRegulatoryAndCommercializationMilestonePayments
Namespace Prefix: | rcus_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Clinical regulatory and commercialization remaining milestone payments. + References No definition available. + Details
Name: | rcus_ClinicalRegulatoryAndCommercializationRemainingMilestonePayments
Namespace Prefix: | rcus_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Collaboration term for current and future clinical programs. + References No definition available. + Details
Name: | rcus_CollaborationTermForCurrentAndFutureClinicalPrograms
Namespace Prefix: | rcus_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Consultant and legal fees. + References No definition available. + Details
Name: | rcus_ConsultantAndLegalFees
Namespace Prefix: | rcus_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Contingent milestone payments receivable. + References No definition available. + Details
Name: | rcus_ContingentMilestonePaymentsReceivable
Namespace Prefix: | rcus_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Contract with customer initial transaction price. + References No definition available. + Details
Name: | rcus_ContractWithCustomerInitialTransactionPrice
Namespace Prefix: | rcus_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Contractual obligation remaining amount not obligated to pay. + References No definition available. + Details
Name: | rcus_ContractualObligationRemainingAmountNotObligatedToPay
Namespace Prefix: | rcus_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Current and future programs exclusive access period. + References No definition available. + Details
Name: | rcus_CurrentAndFutureProgramsExclusiveAccessPeriod
Namespace Prefix: | rcus_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Deferred revenue related to development and commercialization services. + References No definition available. + Details
Name: | rcus_DeferredRevenueRelatedToDevelopmentAndCommercializationServices
Namespace Prefix: | rcus_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Deferred revenue related to domvanalimab option. + References No definition available. + Details
Name: | rcus_DeferredRevenueRelatedToDomvanalimabOption
Namespace Prefix: | rcus_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Deferred Revenue related to etrumadenant option. + References No definition available. + Details
Name: | rcus_DeferredRevenueRelatedToEtrumadenantOption
Namespace Prefix: | rcus_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Deferred revenue related to research and development pipeline. + References No definition available. + Details
Name: | rcus_DeferredRevenueRelatedToResearchAndDevelopmentPipeline
Namespace Prefix: | rcus_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Development milestone expense. + References No definition available. + Details
Name: | rcus_DevelopmentMilestoneExpense
Namespace Prefix: | rcus_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Development milestone payments. + References No definition available. + Details
Name: | rcus_DevelopmentMilestonePayments
Namespace Prefix: | rcus_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Direct offering cost. + References No definition available. + Details
Name: | rcus_DirectOfferingCost
Namespace Prefix: | rcus_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Domvanalimab option payment upon achievement of certain development milestones. + References No definition available. + Details
Name: | rcus_DomvanalimabOptionPaymentUponAchievementOfCertainDevelopmentMilestones
Namespace Prefix: | rcus_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Estimated performance period of agreement. + References No definition available. + Details
Name: | rcus_EstimatedPerformancePeriodOfAgreement
Namespace Prefix: | rcus_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Fee incurred with third party upon receipt of option exercise payments. + References No definition available. + Details
Name: | rcus_FeeIncurredWithThirdPartyUponReceiptOfOptionExercisePayments
Namespace Prefix: | rcus_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Fees allocated among performance obligations. + References No definition available. + Details
Name: | rcus_FeesAllocatedAmongPerformanceObligations
Namespace Prefix: | rcus_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Funds received for stock purchase agreement. + References No definition available. + Details
Name: | rcus_FundsReceivedForStockPurchaseAgreement
Namespace Prefix: | rcus_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Increase (decrease) in operating expenses. + References No definition available. + Details
Name: | rcus_IncreaseDecreaseInOperatingExpenses
Namespace Prefix: | rcus_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition License and collaboration agreements. + References No definition available. + Details
Name: | rcus_LicenseAndCollaborationAgreementsLineItems
Namespace Prefix: | rcus_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Maximum ownership percentage of outstanding common stock remain unchanged. + References No definition available. + Details
Name: | rcus_MaximumOwnershipPercentageOfOutstandingCommonStockRemainUnchanged
Namespace Prefix: | rcus_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Milestone expense. + References No definition available. + Details
Name: | rcus_MilestoneExpense
Namespace Prefix: | rcus_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Milestone payments. + References No definition available. + Details
Name: | rcus_MilestonePayments
Namespace Prefix: | rcus_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Non refundable and non creditable cash payments. + References No definition available. + Details
Name: | rcus_NonRefundableAndNonCreditableCashPayments
Namespace Prefix: | rcus_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Non refundable and non creditable upfront cash payments. + References No definition available. + Details
Name: | rcus_NonRefundableAndNonCreditableUpfrontCashPayments
Namespace Prefix: | rcus_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Number of exercise option to programs. + References No definition available. + Details
Name: | rcus_NumberOfExerciseOptionToPrograms
Namespace Prefix: | rcus_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of research programs. + References No definition available. + Details
Name: | rcus_NumberOfResearchPrograms
Namespace Prefix: | rcus_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Option continuation payment due upon second anniversary of agreement. + References No definition available. + Details
Name: | rcus_OptionContinuationPaymentDueUponSecondAnniversaryOfAgreement
Namespace Prefix: | rcus_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Option continuation payment receivable upon eighth anniversary of agreement. + References No definition available. + Details
Name: | rcus_OptionContinuationPaymentReceivableUponEighthAnniversaryOfAgreement
Namespace Prefix: | rcus_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Option continuation payment receivable upon fourth anniversary of agreement. + References No definition available. + Details
Name: | rcus_OptionContinuationPaymentReceivableUponFourthAnniversaryOfAgreement
Namespace Prefix: | rcus_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Option continuation payment receivable upon sixth anniversary of agreement. + References No definition available. + Details
Name: | rcus_OptionContinuationPaymentReceivableUponSixthAnniversaryOfAgreement
Namespace Prefix: | rcus_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Option ending period. + References No definition available. + Details
Name: | rcus_OptionEndingPeriod
Namespace Prefix: | rcus_
Data Type: | xbrli:gYearMonthItemType
Balance Type: | na
Period Type: | duration

X
- Definition Option fee per program for all other programs entering clinical development to exercise option. + References No definition available. + Details
Name: | rcus_OptionFeePerProgramForAllOtherProgramsEnteringClinicalDevelopmentToExerciseOption
Namespace Prefix: | rcus_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Option payment received. + References No definition available. + Details
Name: | rcus_OptionPaymentReceived
Namespace Prefix: | rcus_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Option payment upon achievement of certain development milestones. + References No definition available. + Details
Name: | rcus_OptionPaymentUponAchievementOfCertainDevelopmentMilestones
Namespace Prefix: | rcus_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Option payment upon completion of certain IND-enabling activities. + References No definition available. + Details
Name: | rcus_OptionPaymentUponCompletionOfCertainIndEnablingActivities
Namespace Prefix: | rcus_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Option period. + References No definition available. + Details
Name: | rcus_OptionPeriod
Namespace Prefix: | rcus_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Payment for first option exercise. + References No definition available. + Details
Name: | rcus_PaymentForFirstOptionExercise
Namespace Prefix: | rcus_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Payment for option exercise. + References No definition available. + Details
Name: | rcus_PaymentForOptionExercise
Namespace Prefix: | rcus_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Percentage of option to purchase maximum shares of common stock. + References No definition available. + Details
Name: | rcus_PercentageOfOptionToPurchaseMaximumSharesOfCommonStock
Namespace Prefix: | rcus_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of premium purchase price of common stock. + References No definition available. + Details
Name: | rcus_PercentageOfPremiumPurchasePriceOfCommonStock
Namespace Prefix: | rcus_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Performance obligation period. + References No definition available. + Details
Name: | rcus_PerformanceObligationPeriod
Namespace Prefix: | rcus_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Period over common stock to be purchased. + References No definition available. + Details
Name: | rcus_PeriodOverCommonStockToBePurchased
Namespace Prefix: | rcus_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Potential regulatory approval milestones payment receivable related to domvanalimab. + References No definition available. + Details
Name: | rcus_PotentialRegulatoryApprovalMilestonesPaymentReceivableRelatedToDomvanalimab
Namespace Prefix: | rcus_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Range of royalties receivable on net sales. + References No definition available. + Details
Name: | rcus_RangeOfRoyaltiesReceivableOnNetSales
Namespace Prefix: | rcus_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Range of tiered royalty payments on net sales. + References No definition available. + Details
Name: | rcus_RangeOfTieredRoyaltyPaymentsOnNetSales
Namespace Prefix: | rcus_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Remaining capitalized fees at closing. + References No definition available. + Details
Name: | rcus_RemainingCapitalizedFeesAtClosing
Namespace Prefix: | rcus_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Remove option continuation payment under agreement. + References No definition available. + Details
Name: | rcus_RemoveOptionContinuationPaymentUnderAgreement
Namespace Prefix: | rcus_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Royalties payable description. + References No definition available. + Details
Name: | rcus_RoyaltiesPayableDescription
Namespace Prefix: | rcus_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Sales milestone and royalty revenue recognized under license agreement. + References No definition available. + Details
Name: | rcus_SalesMilestoneAndRoyaltyRevenueRecognizedUnderLicenseAgreement
Namespace Prefix: | rcus_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Stock issued during period value determined to premium on purchase of common stock and allocated to performance obligation. + References No definition available. + Details
Name: | rcus_StockIssuedDuringPeriodValueDeterminedToPremiumOnPurchaseOfCommonStockAndAllocatedToPerformanceObligation
Namespace Prefix: | rcus_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Sub license fees incurred. + References No definition available. + Details
Name: | rcus_SubLicenseFeesIncurred
Namespace Prefix: | rcus_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Trailing days average closing price. + References No definition available. + Details
Name: | rcus_TrailingDaysAverageClosingPrice
Namespace Prefix: | rcus_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Upfront and milestone payments. + References No definition available. + Details
Name: | rcus_UpfrontAndMilestonePayments
Namespace Prefix: | rcus_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Upfront cash payment. + References No definition available. + Details
Name: | rcus_UpfrontCashPayment
Namespace Prefix: | rcus_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of amortization expense for asset recognized from cost incurred to obtain or fulfill contract with customer. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 340 -SubTopic 40 -Section 50 -Paragraph 3 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=123353750&loc=SL49131252-203054 + Details
Name: | us-gaap_CapitalizedContractCostAmortization
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount, after accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer; classified as current. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 340 -SubTopic 40 -Section 50 -Paragraph 3 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123353750&loc=SL49131252-203054 + Details
Name: | us-gaap_CapitalizedContractCostNetCurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount, after accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer; classified as noncurrent. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 340 -SubTopic 40 -Section 50 -Paragraph 3 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123353750&loc=SL49131252-203054 + Details
Name: | us-gaap_CapitalizedContractCostNetNoncurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 8 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=123360276&loc=SL49130531-203044 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 45 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=123360276&loc=SL49130533-203044 + Details
Name: | us-gaap_ContractWithCustomerAssetNet
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as noncurrent. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 45 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=123360276&loc=SL49130533-203044 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 8 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=123360276&loc=SL49130531-203044 + Details
Name: | us-gaap_ContractWithCustomerAssetNetNoncurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 45 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=123360276&loc=SL49130532-203044 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=123360276&loc=SL49130531-203044 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 8 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045 + Details
Name: | us-gaap_ContractWithCustomerLiabilityNoncurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(5)) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 + Details
Name: | us-gaap_DeferredRevenue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(5)) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 + Details
Name: | us-gaap_DeferredRevenueCurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of revenue recognized that was previously reported as deferred or unearned revenue. + References No definition available. + Details
Name: | us-gaap_DeferredRevenueRevenueRecognized1
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 912 -SubTopic 730 -Section 25 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 985 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 730 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373 + Details
Name: | us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 730 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373 + Details
Name: | us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 4 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 924 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -URI http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Price of a single share of a number of saleable stocks of a company. + References No definition available. + Details
Name: | us-gaap_SharePrice
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Definition Per share or per unit amount of equity securities issued. + References No definition available. + Details
Name: | us-gaap_SharesIssuedPricePerShare
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number of new stock issued during the period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 + Details
Name: | us-gaap_StockIssuedDuringPeriodSharesNewIssues
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 + Details
Name: | us-gaap_StockIssuedDuringPeriodValueNewIssues
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | srt_CounterpartyNameAxis=rcus_GileadSciencesIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=rcus_WuXiBiologicsLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=rcus_AbmunoLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=rcus_GenentechMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=rcus_OptionLicenseAndCollaborationAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=rcus_TaihoPharmaceuticalCoLtdMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=rcus_CommonStockPurchaseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_PlanNameAxis=rcus_MayTwoThousandTwentyPublicOfferingMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=rcus_AmendedGileadCollaborationAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=rcus_QuemliclustatOptionsLicenseAndResearchAndDevelopmentActivitiesAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=rcus_ResearchAndDevelopmentActivitiesForDomvanalimabMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=rcus_ResearchAndDevelopmentAndCommercializationActivitiesForZimberelimabMonotherapyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=rcus_AccessRightsRelatedToResearchAndDevelopmentPipelineMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=rcus_OptionAndLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=rcus_AstraZenecaAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=rcus_GenentechCollaborationAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |